2025 Q4 -tulosraportti
Äänite tulossa
Tänään
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 75 | - | - | ||
| 109 | - | - | ||
| 14 | - | - | ||
| 1 093 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·2 t sitten · MuokattuI have emailed with Erik Wiklund. Everyone has misunderstood the "Abstract text release" on April 13th and 27th respectively. New data and results will only be available at the conference itself (ASGCT 2026). Neither journalists nor major players have gained access to anything we don't already know, and neither do we. This means that all unnecessary noise here, as well as speculations about possible major players with insider knowledge and new data, DOES NOT hold water! That is only good! - focus on the last 6 lines in the email.
6 t sitten6 t sitten-17% 😭
·7 t sitten · MuokattuThe text below is excerpted from the 2025 and YTD report which will be presented tomorrow. As one can see, Erik & Co have been good at dripping news about the research and various triggers evenly throughout the first months of this year, and even though they now likely have a gag order regarding the content of the abstract to be presented in May until April 27th, it's not entirely unthinkable that something new might emerge during tomorrow's presentation. This will be exciting going forward anyway😊 «Important post-period events YTD 2026: *In January 2026, Circio and The University of Texas Medical Branch jointly announced a collaboration to evaluate circVec for the treatment of infectious diseases *In January 2026, Circio announced that the rights issue was over-subscribed by more than 50%, raising apx. NOK 65 million in gross proceeds from the transaction *In February 2026, Circio completed a directed issue of NOK 3.6 million in connection with the rights issue, bringing total gross proceeds to NOK 68.6 million *In February 2026, Circio presented new and groundbreaking in vivo data showing up to 50-fold enhanced circVec-AAV gene expression in eye *In March 2026, Circio announced that an abstract on its circVec-AAV gene therapy program had been selected for an oral presentation at the prestigious ASGCT annual meeting in Boston in May 2026 *In March 2026, Circio announced a research collaboration in the area of in vivo CAR-Macrophage (CAR-M) therapy with Japanese biotech company United Immunity Co»
·4 t sitten · MuokattuCircio has in 2026 delivered a series of updates, including new preclinical data, research collaborations, and capital raising. The preclinical data show increased expression in the eye, which supports the platform's ability to drive protein production, but does NOT document effect. Collaborations with academic institutions and biotech companies indicate interest in the platform, but are early and WITHOUT validating character. Selection for oral presentation at ASGCT increases credibility, but does not change the case's foundation. Overall, these activities increase the narrative probability.......BUT it does not change the crucial question: whether the system works in practice in CAR-T. This is where the real platform validation happens! That is the paramount question and a dealbreaker for the entire case!·2 t sittenOkay, a negative CAR-T readout does not necessarily mean that the circVec platform does not work, but it will strongly indicate that it does not function in the most demanding and commercially attractive application. This will significantly reduce the platform's relevance and move the case from a broad platform to more narrow applications. What do you think will happen to the company/share price in that situation? This has nothing to do with positive/negative - but a completely neutral and dry statement. DATA is King - we need to see it works, or else it's just a narrative story.
·7 t sittenToday just 0.60 discount on shares Circio therefore people panic then have sold down resistance 8.89 kr I am calm now My held shares shall be high value than loss today because must read news document than here forum is much nonsense
·7 t sittenIs this Danish?
·7 t sitten · MuokattuWe are in a mentally demanding period. Seeing values of hundreds of thousands and millions shrink within a few days is challenging. I still have great faith that this company will be acquired, and that's why I invested heavily in it to begin with. Even though there has been a significant rise, and now a significant correction. Don't forget the carrot waiting ahead. That is what will change your life. Not these green and red percentages this week.
·6 t sitten · MuokattuUp like a deer and down like a turd. This is a pyramid scheme of the worst kind.
·4 t sittenThe big question is why you bother spending time on a forum for a stock you don't believe in? Don't you have better things to do these days?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Äänite tulossa
Tänään
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sitten · MuokattuI have emailed with Erik Wiklund. Everyone has misunderstood the "Abstract text release" on April 13th and 27th respectively. New data and results will only be available at the conference itself (ASGCT 2026). Neither journalists nor major players have gained access to anything we don't already know, and neither do we. This means that all unnecessary noise here, as well as speculations about possible major players with insider knowledge and new data, DOES NOT hold water! That is only good! - focus on the last 6 lines in the email.
- 6 t sitten6 t sitten-17% 😭
- ·7 t sitten · MuokattuThe text below is excerpted from the 2025 and YTD report which will be presented tomorrow. As one can see, Erik & Co have been good at dripping news about the research and various triggers evenly throughout the first months of this year, and even though they now likely have a gag order regarding the content of the abstract to be presented in May until April 27th, it's not entirely unthinkable that something new might emerge during tomorrow's presentation. This will be exciting going forward anyway😊 «Important post-period events YTD 2026: *In January 2026, Circio and The University of Texas Medical Branch jointly announced a collaboration to evaluate circVec for the treatment of infectious diseases *In January 2026, Circio announced that the rights issue was over-subscribed by more than 50%, raising apx. NOK 65 million in gross proceeds from the transaction *In February 2026, Circio completed a directed issue of NOK 3.6 million in connection with the rights issue, bringing total gross proceeds to NOK 68.6 million *In February 2026, Circio presented new and groundbreaking in vivo data showing up to 50-fold enhanced circVec-AAV gene expression in eye *In March 2026, Circio announced that an abstract on its circVec-AAV gene therapy program had been selected for an oral presentation at the prestigious ASGCT annual meeting in Boston in May 2026 *In March 2026, Circio announced a research collaboration in the area of in vivo CAR-Macrophage (CAR-M) therapy with Japanese biotech company United Immunity Co»·4 t sitten · MuokattuCircio has in 2026 delivered a series of updates, including new preclinical data, research collaborations, and capital raising. The preclinical data show increased expression in the eye, which supports the platform's ability to drive protein production, but does NOT document effect. Collaborations with academic institutions and biotech companies indicate interest in the platform, but are early and WITHOUT validating character. Selection for oral presentation at ASGCT increases credibility, but does not change the case's foundation. Overall, these activities increase the narrative probability.......BUT it does not change the crucial question: whether the system works in practice in CAR-T. This is where the real platform validation happens! That is the paramount question and a dealbreaker for the entire case!·2 t sittenOkay, a negative CAR-T readout does not necessarily mean that the circVec platform does not work, but it will strongly indicate that it does not function in the most demanding and commercially attractive application. This will significantly reduce the platform's relevance and move the case from a broad platform to more narrow applications. What do you think will happen to the company/share price in that situation? This has nothing to do with positive/negative - but a completely neutral and dry statement. DATA is King - we need to see it works, or else it's just a narrative story.
- ·7 t sittenToday just 0.60 discount on shares Circio therefore people panic then have sold down resistance 8.89 kr I am calm now My held shares shall be high value than loss today because must read news document than here forum is much nonsense·7 t sittenIs this Danish?
- ·7 t sitten · MuokattuWe are in a mentally demanding period. Seeing values of hundreds of thousands and millions shrink within a few days is challenging. I still have great faith that this company will be acquired, and that's why I invested heavily in it to begin with. Even though there has been a significant rise, and now a significant correction. Don't forget the carrot waiting ahead. That is what will change your life. Not these green and red percentages this week.·6 t sitten · MuokattuUp like a deer and down like a turd. This is a pyramid scheme of the worst kind.·4 t sittenThe big question is why you bother spending time on a forum for a stock you don't believe in? Don't you have better things to do these days?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 75 | - | - | ||
| 109 | - | - | ||
| 14 | - | - | ||
| 1 093 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Äänite tulossa
Tänään
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·2 t sitten · MuokattuI have emailed with Erik Wiklund. Everyone has misunderstood the "Abstract text release" on April 13th and 27th respectively. New data and results will only be available at the conference itself (ASGCT 2026). Neither journalists nor major players have gained access to anything we don't already know, and neither do we. This means that all unnecessary noise here, as well as speculations about possible major players with insider knowledge and new data, DOES NOT hold water! That is only good! - focus on the last 6 lines in the email.
- 6 t sitten6 t sitten-17% 😭
- ·7 t sitten · MuokattuThe text below is excerpted from the 2025 and YTD report which will be presented tomorrow. As one can see, Erik & Co have been good at dripping news about the research and various triggers evenly throughout the first months of this year, and even though they now likely have a gag order regarding the content of the abstract to be presented in May until April 27th, it's not entirely unthinkable that something new might emerge during tomorrow's presentation. This will be exciting going forward anyway😊 «Important post-period events YTD 2026: *In January 2026, Circio and The University of Texas Medical Branch jointly announced a collaboration to evaluate circVec for the treatment of infectious diseases *In January 2026, Circio announced that the rights issue was over-subscribed by more than 50%, raising apx. NOK 65 million in gross proceeds from the transaction *In February 2026, Circio completed a directed issue of NOK 3.6 million in connection with the rights issue, bringing total gross proceeds to NOK 68.6 million *In February 2026, Circio presented new and groundbreaking in vivo data showing up to 50-fold enhanced circVec-AAV gene expression in eye *In March 2026, Circio announced that an abstract on its circVec-AAV gene therapy program had been selected for an oral presentation at the prestigious ASGCT annual meeting in Boston in May 2026 *In March 2026, Circio announced a research collaboration in the area of in vivo CAR-Macrophage (CAR-M) therapy with Japanese biotech company United Immunity Co»·4 t sitten · MuokattuCircio has in 2026 delivered a series of updates, including new preclinical data, research collaborations, and capital raising. The preclinical data show increased expression in the eye, which supports the platform's ability to drive protein production, but does NOT document effect. Collaborations with academic institutions and biotech companies indicate interest in the platform, but are early and WITHOUT validating character. Selection for oral presentation at ASGCT increases credibility, but does not change the case's foundation. Overall, these activities increase the narrative probability.......BUT it does not change the crucial question: whether the system works in practice in CAR-T. This is where the real platform validation happens! That is the paramount question and a dealbreaker for the entire case!·2 t sittenOkay, a negative CAR-T readout does not necessarily mean that the circVec platform does not work, but it will strongly indicate that it does not function in the most demanding and commercially attractive application. This will significantly reduce the platform's relevance and move the case from a broad platform to more narrow applications. What do you think will happen to the company/share price in that situation? This has nothing to do with positive/negative - but a completely neutral and dry statement. DATA is King - we need to see it works, or else it's just a narrative story.
- ·7 t sittenToday just 0.60 discount on shares Circio therefore people panic then have sold down resistance 8.89 kr I am calm now My held shares shall be high value than loss today because must read news document than here forum is much nonsense·7 t sittenIs this Danish?
- ·7 t sitten · MuokattuWe are in a mentally demanding period. Seeing values of hundreds of thousands and millions shrink within a few days is challenging. I still have great faith that this company will be acquired, and that's why I invested heavily in it to begin with. Even though there has been a significant rise, and now a significant correction. Don't forget the carrot waiting ahead. That is what will change your life. Not these green and red percentages this week.·6 t sitten · MuokattuUp like a deer and down like a turd. This is a pyramid scheme of the worst kind.·4 t sittenThe big question is why you bother spending time on a forum for a stock you don't believe in? Don't you have better things to do these days?
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 75 | - | - | ||
| 109 | - | - | ||
| 14 | - | - | ||
| 1 093 | - | - | ||
| 100 | - | - |
Välittäjätilasto
Dataa ei löytynyt